San Luis Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

San Luis Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$48.8K	–	188
2025 Q3	$48.8K	Hold	10,000	–	–	0.01%	173
2025 Q2	$51K	Sell	10,000 -150	-1%	-$737	0.01%	137
2025 Q1	$54K	Buy	+10,150	New	+$74K	0.01%	133
2024 Q4	–	Sell	-10,500	Closed	-$69K	–	153
2024 Q3	$69K	Buy	+10,500	New	+$75.3K	0.01%	141

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

San Luis Wealth Advisors's RXRX Position: Q4 2025 in Review

San Luis Wealth Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 10,000 shares — an estimated $48.8K sold.

San Luis Wealth Advisors first reported a position in RXRX in Q3 2024 and held it in 4 quarters. The position peaked at $69K in Q3 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

San Luis Wealth Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
San Luis Wealth Advisors sold 10,000 Recursion Pharmaceuticals shares in Q4 2025, an estimated $48.8K.
San Luis Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 4 quarters.
San Luis Wealth Advisors's Recursion Pharmaceuticals position peaked at $69K in Q3 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on San Luis Wealth Advisors's 13F filing for Q4 2025, filed 26 Jan 2026.